Randomized controlled clinical trial on the treatment of Thymosin-a1 vs interferon-&alpha; in patients with hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

286

HTML

2184

Tables (1-2)

136

Sum=2606

Jun 15, 2001 (publication date) through Apr 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Jun 15, 2001; 7(3): 411-414
Published online Jun 15, 2001. doi: 10.3748/wjg.v7.i3.411

Table 1 Responses to treatment at the end of therapy n (%)

	T-a1 (n = 18)	IFN-α (n = 33)	HC (n = 30)
	(after 6 mo of follow-up)
ALT normalization	7 (38.9)	16 (48.5)	5 (16.7)
HBV DNA-negative	10 (55.6)^b	22 (66.7)^b	2 (6.7)
ALT normal/HBV DNA and HBeAg-negative	6 (33.3)	15 (45.5)^b	1 (3.3)

^bP < 0.01, vs HC.

Citation: You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, Wu RX, Zhang HL, Zhang YM, Yan SM, Zhang L. Randomized controlled clinical trial on the treatment of Thymosin-a1 vs interferon-α in patients with hepatitis B. World J Gastroenterol 2001; 7(3): 411-414
URL: https://www.wjgnet.com/1007-9327/full/v7/i3/411.htm
DOI: https://dx.doi.org/10.3748/wjg.v7.i3.411